1. process development of peptide or protein APIs from microbial or human recombinant fermentation processes
2. formulation development of biological injectable
3. manufacturing capacities of biological APIs, lyophilized injectable, and prefilled syringe/cartridge for preclinical, clinical, and commercial uses

TBMC will leverage existing resources to integrate intelligent and smart platform to establish various biopharmaceuticals manufacturing facility.

ORAL PEPTIDE
Summary of development timelines-product
MIRA/JER Design
Lead Optimization
Preclinical Studies
Phase I
Phase II
Phase III
ANY002 Oral GLP1 product A: Prototype with human PK results available
ANY004 Oral GLP1 product B: Prototype in animal study
ANY003 Novel TNFα Inhibitor: Lead optimization
ANYOOX Open for collaboration